News

‘Practice-changing’ interventional cardiology research grabs ACC.26 spotlight

The second day of the American College of Cardiology’s annual conference started with a series of highly anticipated interventional cardiology trials.

Stavros V. Konstantinides, MD, PhD, presenting data at ACC.26

Catheter-based treatment linked to major benefits for intermediate-risk PE

New 30-day data presented at ACC.26 helped answer questions cardiologists have had been asking for years. “Thank you for bringing PE into the future," one vascular specialist said from the stage.

FDA sees promise in voice-based AI model for heart failure

An advanced algorithm that looks for signs of heart failure in five-second voice recordings has received the FDA's breakthrough device designation.

Breast cancer screening rates saw a 10% drop among several groups of women over the last 2 decades

Decreased screening rates among different subgroups highlight the ongoing need for outreach strategies that target vulnerable populations, experts contend.

Medtronic’s MiniMed 780G automated insulin delivery system

Software errors lead to major insulin pump recall—manufacturer shares a fix

Nearly 27,000 MiniMed 780G insulin pumps were included in a new Class II recall. By taking a few basic steps, however, patients should be able to avoid any significant risks.

William P. Shutze, MD, FACS, secretary of the Society of Vascular Surgery (SVS), a vascular surgeon with Texas Vascular Associates in Plano, Texas, and a clinical associate professor of medicine at Texas A&M College of Medicine, explained the role of vascular surgeons in peripheral artery disease (PAD) and critical limb ischemia (CLI).

Getting vascular surgeons more involved leads to key improvements for PAD patients

Vascular surgeons perform procedures interventional cardiologists and interventional radiologists do not do—so why not make sure they are part of every heart team conversation?

Northwestern deploys new mobile stroke unit equipped with 32-slice CT scanner

The MSU operates 365 days a year and covers 138 square miles. Hundreds of patients have been treated through the MSU, with more than 500 receiving critical care in it 2025 alone.

Activist investors sue UnitedHealth to force annual reporting on patient care access

Led by a Quebec-based faith organization, a coalition of investors is asking a court to force UnitedHealth to provide details on the social impacts of its history of mergers and acquisitions. The lawsuit comes after the plaintiffs, all company shareholders, failed to get the proposal passed through internal channels. The Securities and Exchange Commission has also opted not to intervene.

doctor examines patient data on their tablet

TAVR technology keeps evolving, improving outcomes without compromising valve performance

TAVR is a go-to treatment for symptomatic severe aortic stenosis in much of the world, thanks in large part to the hard work of research teams that never stop looking for new, innovative ways to make the technology more effective.

Q&A: How supra-annular, self-expanding TAVR valves open up options for future interventions

TAVR procedures have surged more than 30% since 2020, with more than 107,000 patients receiving a new prosthetic valve in 2023 alone. As this trend continues, it’s increasingly important that cardiologists consider the long-term impact on future coronary interventions patients may need.

Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.

Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Daniel Judge, MD, director of the cardiovascular genetics program, Medical University of South Carolina, the Edwin W. and Teresa H. Rogers Endowed Chair for Cardiovascular Research, Medical University of South Carolina, presented the results of the late-breaking ATTRibute-CM study for the drug acoramidis used to treat transthyretin amyloidosis at AHA 2024.

ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data

Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.

Around the web

Cardiovascular Business

‘Practice-changing’ interventional cardiology research grabs ACC.26 spotlight

The second day of the American College of Cardiology’s annual conference started with a series of highly anticipated interventional cardiology trials.